Insights & news

Medicines – Publication of Regulation (EU) 2019/5 of 11 December 2018 amending Regulation (EC) No 726/2004 – Key Novelties

  • 08/01/2019
  • Articles

On 7 January 2019, the Official Journal of the European Union published a Regulation amending the EU regulatory framework governing medicinal products. The attached memorandum discusses the key changes brought about by the Regulation.

Attachments:

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 14/01/2019
    • Articles

    General Court of European Union Confirms Withdrawal Of Orphan Medicine Status Because Cancer Medicine Elotuzumab No Longer Offers Significant Benefit Over Alternative Treatment

    On 5 December 2018, the General Court of the European Union dismissed an action for annulment of a decision of the European Commission which had found that elotuzumab, a medicine indicated for the treatment of multiple myeloma, no longer satisfied the criteria for designation as an orphan medicinal product. Please find attached a case note which discusses this judgment.

    Read more
    • 10/01/2019
    • Articles

    Veterinary Medicinal Products - Publication of Regulation (EU) 2019/6

    After four years of negotiations, Regulation (EU) 2019/6 governing veterinary medicinal products was adopted on 11 December 2018 and officially published on 7 January 2019. The new Regulation, which will apply as of 28 January 2022, aims to establish a modern regulatory framework for veterinary medicinal products. The attached memorandum discusses its most striking features.

    Read more
    • 27/12/2018
    • Articles

    General Court Reviews New Set of Patent Settlement Agreements In Pharmaceutical Sector (Servier and Others)

    In a series of judgments earlier this month, the General Court of the European Union had again occasion to review patent settlement agreements in the pharmaceutical sector. The General Court delivered a mixed verdict in that it held that: i. as a general matter, patent settlement agreements should be encouraged and are pro-competitive; ii. settlement agreements which do not merely end litigation, but also give benefits to generic companies as a form of compensation to refrain from entering the market constitute a restriction by object of competition. iii. in limiting the relevant product market to a single active substance, the European Commission defined that market too narrowly, thus erroneously imputing a dominant position to Servier. Please find attached a case-note discussing these judgments.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *